Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FJUU9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,591.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Nucala 100 mg/ml auto-injector on December 8, 2025, with an ultimate completion date of December 9, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (SPE2DR) awarded under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide recurring pharmaceutical supply support to Department of Defense military healthcare facilities worldwide.
Nucala (mepolizumab) is a biologic immunosuppressant agent used in the treatment of eosinophilic asthma and other inflammatory conditions. As a prime vendor contractor under PPV-G GEN V, DMS Pharmaceutical Group supplies a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and specialty medical consumables to support DoD healthcare operations. The parent contract, valued at $499,999,999 with an ultimate completion date of December 31, 2036, establishes DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical supply chain with demonstrated performance across multiple therapeutic categories and product lines.
Quick answers
Who was awarded contract SPE2DR26FJUU9?
SPE2DR26FJUU9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FJUU9 worth?
The government has obligated $11,591 on SPE2DR26FJUU9.
Is contract SPE2DR26FJUU9 an order under another contract?
Yes. SPE2DR26FJUU9 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUU9 competed?
The extent of competition for SPE2DR26FJUU9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award